MMV253

Zydus Cadila

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
MoA
  • Unknown 

Key features
  • Predicted 280-520mg human dose gives concentrations above Minimal Parasiticidal Concentration for >6 days

  • Low resistance potential from in vitro studies

Challenges
  • Synthesis and cost of goods

Status
  • First-in-Human study started in February 2019

Next milestone
  • Confirm human pharmacokinetics and efficacy
Previously
  • Name AZ13721412; from a discovery partnership between MMV and AstraZeneca, Bangalore

MMV Project Director
  • Illaria Di Resta